NeuroPace Inc
NPCE
Get informed when a big investor buys or sells
+ FollowMarket Cap$443.13M
Close$
Share Statistics
| Market cap | $443.13 Million |
|---|---|
| Enterprise Value | $500.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.66 |
| Beta | 1.87 |
| Outstanding Shares | 34,104,430 |
Return
| Return on Equity | -160.85% |
|---|---|
| Return on Assets | -19.71% |
| Return on Invested Capital | -18.35% |
Valuation & Multiples
| P/E Ratio | -22.58 |
|---|---|
| PEG | - |
| Price to Sales | 6.46 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.07 |
| Enterprise Value to EBIT | -34.3 |
| Enterprise Value to Net Income | -27 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 5.9 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$22.61 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$27.13 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 78.17%▼ 0.30% |
|---|---|
| Total Invested | $423.69M▲ 21.80% |
| Investors Holding | 115▲ 1.00% |
ESG Score
No data
About NeuroPace Inc
152 employeesBased in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and ...